부산대학교 도서관

Reddy MB; Clinical Pharmacology, Oncology, Pfizer Inc., Boulder, Colorado, USA.; Cabalu TD; DMPK, Pharmacokinetics, Dynamics, Metabolism, and Bioanalytics, Merck & Co., Inc., Rahway, New Jersey, USA.; de Zwart L; DMPK, Janssen Pharmaceutica NV, A Johnson & Johnson Company, Beerse, Belgium.; Ramsden D; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts, USA.; Dowty ME; Pharmacokinetics Dynamics and Metabolism, Pfizer Inc, Cambridge, Massachusetts, USA.; Taskar KS; DMPK, Pre-Clinical Sciences, Research Technologies, GSK, Stevenage, UK.; Badée J; PK Sciences, Biomedical Research, Novartis, Basel, Switzerland.; Bolleddula J; Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA.; Boulu L; Modeling and Simulation, Translational Medicine and Early Development, Sanofi, Montpellier, France.; Fu Q; Modeling and Simulation, Vertex Pharmaceuticals, Boston, Massachusetts, USA.; Kotsuma M; Quantitative Clinical Pharmacology, Daiichi Sankyo Co., Ltd., Tokyo, Japan.; Leblanc AF; Quantitative, Translational & ADME Sciences, Development Science, AbbVie, North Chicago, Illinois, USA.; Lewis G; DMPK, Pre-Clinical Sciences, Research Technologies, GSK, Stevenage, UK.; Liang G; DMPK, Vertex Pharmaceuticals, Boston, Massachusetts, USA.; Parrott N; Pharmaceutical Sciences, Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pilla Reddy V; Global PKPD/Pharmacometrics, Eli Lilly and Company, Bracknell, UK and Indianapolis, Indiana, USA.; Prakash C; DMPK and Clinical Pharmacology, Agios, Cambridge, Massachusetts, USA.; Shah K; Quantitative Clinical Pharmacology, Takeda Pharmaceuticals International Inc., Cambridge, Massachusetts, USA.; Umehara K; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Mukherjee D; Quantitative Clinical Pharmacology, Daiichi-Sankyo Inc., Basking Ridge, New Jersey, USA.; Rehmel J; Global PKPD/Pharmacometrics, Eli Lilly and Company, Bracknell, UK and Indianapolis, Indiana, USA.; Hariparsad N; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts, USA.

Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE

van Groen, B.D.; Pilla Reddy, V.; Badée, J.; Olivares-Morales, A.; Johnson, T.N.; Nicolaï, J.; Annaert, P.; Smits, A.; de Wildt, S.N.; Knibbe, C.A.J.; de Zwart, L.

Clin Transl Sci
Clinical and Translational Science, Vol 14, Iss 1, Pp 29-35 (2021)
Cts-Clinical and Translational Science, 14, 1, pp. 29-35

Asiimwe IG; The Wolfson Centre for Personalized Medicine, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.; APT-Africa Fellowship Program, c/o Pharmacometrics Africa NPC, Groote Schuur Hospital, Cape Town, South Africa.; Chtiba N; Pharmacy of Monastir, University of Monastir, Monastir, Tunisia.; Mouksassi S; Certara, Cairo, Egypt.; Pillai GC; APT-Africa Fellowship Program, c/o Pharmacometrics Africa NPC, Groote Schuur Hospital, Cape Town, South Africa.; Division of Clinical Pharmacology, University of Cape Town, South Africa.; CP+ Associates GmbH, Basel, Switzerland.; Peter RM; Global PKPD/Pharmacometrics, Eli Lilly and Company, Bracknell, UK.; Yuen E; Global PKPD/Pharmacometrics, Eli Lilly and Company, Bracknell, UK.; Pilla Reddy V; Global PKPD/Pharmacometrics, Eli Lilly and Company, Bracknell, UK.

Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2163-8306 (Electronic) Linking ISSN: 21638306 NLM ISO Abbreviation: CPT Pharmacometrics Syst Pharmacol Subsets: MEDLINE

Reynolds K; U.S. Food and Drug Administration, Silver Spring, Maryland, USA.; Yang X; U.S. Food and Drug Administration, Silver Spring, Maryland, USA.; Peters SA; European Federation of Pharmaceutical Industries and Associations, Ingelheim, Germany.; Sinha V; Pharmaceutical Research and Manufacturers of America, Washington, DC, USA.; Heymann H; U.S. Food and Drug Administration, Silver Spring, Maryland, USA.; Borges LN; Brazilian Health Regulatory Agency, Brasília, Brazil.; Einolf HJ; Pharmaceutical Research and Manufacturers of America, Washington, DC, USA.; Fu S; National Medical Products Administration, Beijing, China.; Hoshino M; Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.; Li L; National Medical Products Administration, Beijing, China.; Lindhagen E; Swedish Medical Products Agency, Uppsala, Sweden.; Miyoshi S; Japan Pharmaceutical Manufacturers Association, Tokyo, Japan.; Mizuno K; Japan Pharmaceutical Manufacturers Association, Tokyo, Japan.; Pilla Reddy V; European Federation of Pharmaceutical Industries and Associations, Bracknell, UK.; Roost MS; Swissmedic, Bern, Switzerland.; Shigemi R; Japan Pharmaceutical Manufacturers Association, Tokyo, Japan.; Tao X; International Federation of Pharmaceutical Manufacturers and Associations, Shanghai, China.; Yang MS; Center for Drug Evaluation, Taipei, Chinese Taipei.; Zhao S; International Federation of Pharmaceutical Manufacturers and Associations, Shanghai, China.; Versantvoort C; Medicines Evaluation Board, Utrecht, The Netherlands.; Ishiguro A; Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.; Madabushi R; U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE

Swapna, Reddi; Srinivas, Pilla; Mahesh, V; Kanth, M. Krishna; JansiRani, D.; Arulraj, S.

2025 Third International Conference on Emerging Applications of Material Science and Technology (ICEAMST) Emerging Applications of Material Science and Technology (ICEAMST), 2025 Third International Conference on. :1697-1703 Nov, 2025

Dogterom P; Riesenberg R; de Greef R; Dennie J; Johnson M; Pilla Reddy V; Miltenburg AMM; Findling RL; Jakate A; Carrothers TJ; Troyer MD

Drug Design, Development and Therapy, Vol 12, Pp 2677-2693 (2018)

J Harikrishna; Vasili Pradeep; V Devika Reddy; M Krishna Kumar; A Surekha; Pilla S Surya Durga Devi; Alladi Mohan

Journal of Clinical and Scientific Research, Vol 10, Iss 2, Pp 115-117 (2021)

Harikrishna, J.; Pradeep, Vasili; Reddy, V.; Kumar, M.; Surekha, A.; Devi, Pilla Surya Durga; Mohan, Alladi

Journal of Clinical and Scientific Research. April-June, 2021, Vol. 10 Issue 2, p115.

Berezowska M; Clinical Pharmacology and Quantitative Pharmacology, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Sharma P; Clinical Pharmacology and Quantitative Pharmacology, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Pilla Reddy V; Clinical Pharmacology and Quantitative Pharmacology, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Coppola P; Clinical Pharmacology and Quantitative Pharmacology, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Publisher: Blackwell Science Country of Publication: England NLM ID: 8710411 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1472-8206 (Electronic) Linking ISSN: 07673981 NLM ISO Abbreviation: Fundam Clin Pharmacol Subsets: MEDLINE

Forte-Soto P; Parexel Early Phase Clinical Unit, London, United Kingdom.; Albayaty M; Parexel Early Phase Clinical Unit, London, United Kingdom.; Patient Safety, Chief Medical Office, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Brooks D; Patient Safety, Chief Medical Office, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.; Arends RH; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.; Tillinghast J; Data Science and Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.; Aksyuk AA; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.; Bouquet J; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, California, USA.; Chen C; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, California, USA.; Gebre A; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.; Kubiak RJ; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.; Pilla Reddy V; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Seegobin S; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Streicher K; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.; Templeton A; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Esser MT; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.

Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE

Pilla Reddy, V; Petersson, K J; Suleiman, A A; Vermeulen, An; Proost, J H; Friberg, L E

CPT Pharmacometrics Syst Pharmacol

Rachel A. Bender Ignacio; David A. Wohl; Rosalin Arends; Venkatesh Pilla Reddy; Ying Mu; Arzhang Cyrus Javan; Michael D. Hughes; Joseph J. Eron; Judith S. Currier; Davey Smith; Kara W. Chew; Michael Gibbs; Courtney V. Fletcher

Clin Pharmacol Ther
Clinical Pharmacology & Therapeutics, vol 112, iss 6

Hariparsad N; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts, USA.; Ramsden D; Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.; Taskar K; Drug Metabolism and Pharmacokinetics, IVIVT, GlaxoSmithKline, Stevenage, UK.; Badée J; PK Sciences, Novartis Institutes for Biomedical Research, Basel, Switzerland.; Venkatakrishnan K; EMD Serono Research & Development Institute, Inc, Billerica, Massachusetts, USA.; Merck KGaA, Darmstadt, Germany.; Reddy MB; Department of Clinical Pharmacology, Oncology, Pfizer, Boulder, Colorado, USA.; Cabalu T; Merck & Co., Inc., Kenilworth, New Jersey, USA.; Mukherjee D; Clinical Pharmacology & Pharmacometrics, AbbVie, Inc., North Chicago, Illinois, USA.; Rehmel J; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.; Bolleddula J; EMD Serono Research & Development Institute, Inc, Billerica, Massachusetts, USA.; Merck KGaA, Darmstadt, Germany.; Emami Riedmaier A; Bristol Meyers Squibb, Princeton, New Jersey, USA.; Prakash C; Agios Pharmaceuticals, Cambridge, Massachusetts, USA.; Chanteux H; UCB Biopharma, QP-DMPK, Brussels, Belgium.; Mao J; Department of Drug Metabolism and Pharmacokinetics, Genentech, A Member of the Roche Group, South San Francisco, California, USA.; Umehara K; Pharmaceutical Sciences, Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Shah K; Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.; De Zwart L; DMPK, Janssen Research and Development, Beerse, Belgium.; Dowty M; Department of Pharmacokinetics, Dynamic, and Metabolism, Pfizer, Cambridge, Massachusetts, USA.; Kotsuma M; Quantitative Clinical Pharmacology, Daiichi-Sankyo, Inc., New Jersey, USA.; Li M; Pharmacokinetics, Dynamics and Metabolism, Sanofi, Bridgewater, New Jersey, USA.; Pilla Reddy V; Clinical Pharmacology and Pharmacometrics, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.; McGinnity DF; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.; Parrott N; Pharmaceutical Sciences, Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.

Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE

Pilla Reddy V; Modelling & Simulation, Early Oncology, R&D Oncology, AstraZeneca, Cambridge, UK.; Clinical Pharmacology and Quantitative Pharmacology, R&D, AstraZeneca, Cambridge, UK.; El-Khateeb E; Centre for Applied Pharmacokinetic Research, University of Manchester, Manchester, UK.; Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.; Jo H; Modelling & Simulation, Early Oncology, R&D Oncology, AstraZeneca, Cambridge, UK.; Giovino N; Early Oncology Clinical, R&D Oncology, AstraZeneca, Boston, USA.; Lythgoe E; R&D Biopharmaceuticals, AstraZeneca, Cambridge, UK.; Sharma S; Clinical Pharmacology and Quantitative Pharmacology, R&D, AstraZeneca, USA.; Tang W; Clinical Pharmacology and Quantitative Pharmacology, R&D, AstraZeneca, USA.; Jamei M; Certara UK Limited, Simcyp Division, Sheffield, UK.; Rastomi-Hodjegan A; Centre for Applied Pharmacokinetic Research, University of Manchester, Manchester, UK.; Certara UK Limited, Simcyp Division, Sheffield, UK.

Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE

Oi Yan Chan J; Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Moullet M; Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Williamson B; UCB UK Ltd, Slough, United Kingdom.; Arends RH; Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.; Pilla Reddy V; Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.

Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE

Loo YM; Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.; McTamney PM; Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.; Arends RH; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.; Abram ME; Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.; Aksyuk AA; Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.; Diallo S; Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.; Flores DJ; Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.; Kelly EJ; Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.; Ren K; Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.; Roque R; Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.; Rosenthal K; Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.; Streicher K; Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.; Tuffy KM; Translational Medicine, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.; Bond NJ; Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, Granta Park, Cambridge CB21 6GH, UK.; Cornwell O; Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, Granta Park, Cambridge CB21 6GH, UK.; Bouquet J; Integrated Bioanalysis, Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, San Francisco, CA 94080, USA.; Cheng LI; Oncology Safety Pathology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.; Dunyak J; Clinical Pharmacology and Pharmacometrics, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.; Huang Y; Integrated Bioanalysis, Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, San Francisco, CA 94080, USA.; Rosenbaum AI; Integrated Bioanalysis, Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, San Francisco, CA 94080, USA.; Pilla Reddy V; Clinical Pharmacology and Pharmacometrics, BioPharmaceuticals R&D, AstraZeneca, Granta Park, Cambridge CB21 6GH, UK.; Andersen H; BIOQUAL Inc., Rockville, MD 20850, USA.; Carnahan RH; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.; Crowe JE Jr; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.; Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN 37232, USA.; Kuehne AI; USAMRIID, Fort Detrick, MD 21702-5011, USA.; Herbert AS; USAMRIID, Fort Detrick, MD 21702-5011, USA.; Dye JM; USAMRIID, Fort Detrick, MD 21702-5011, USA.; Bright H; Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.; Kallewaard NL; Virology and Vaccine Discovery, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.; Pangalos MN; BioPharmaceuticals R&D, AstraZeneca, Cambridge CB21 6GH, UK.; Esser MT; Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.

Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE

Pilla Reddy V; Modelling and Simulation, Early Oncology, Oncology R&D, AstraZeneca, Cambridge, UK.; Clinical Pharmacology and Quantitative Pharmacology, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Jo H; Modelling and Simulation, Early Oncology, Oncology R&D, AstraZeneca, Cambridge, UK.; Certara UK Ltd, Simcyp Division, Sheffield, UK.; Neuhoff S; Certara UK Ltd, Simcyp Division, Sheffield, UK.

Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE

Pilla Reddy V; Early Oncology, Oncology Research & Development, AstraZeneca, Cambridge, UK. Venkatesh.Reddy@astrazeneca.com.; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals Research & Development, AstraZeneca, Cambridge, UK. Venkatesh.Reddy@astrazeneca.com.; Fretland AJ; Early Oncology, Oncology Research & Development, AstraZeneca, Boston, MA, USA.; Zhou D; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals Research & Development, AstraZeneca, Boston, MA, USA.; Sharma S; Quantitative Clinical Pharmacology, AstraZeneca , South San Francisco, CA, USA.; Chen B; Quantitative Clinical Pharmacology, AstraZeneca , South San Francisco, CA, USA.; Vishwanathan K; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals Research & Development, AstraZeneca, Boston, MA, USA.; McGinnity DF; Early Oncology, Oncology Research & Development, AstraZeneca, Cambridge, UK.; Xu Y; Quantitative Clinical Pharmacology, AstraZeneca , South San Francisco, CA, USA.; Ware JA; Quantitative Clinical Pharmacology, AstraZeneca , South San Francisco, CA, USA.

Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

Koneru B; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Department of Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Department of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Farooqi A; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Nguyen TH; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Chen WH; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Hindle A; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Department of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Eslinger C; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Makena MR; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Burrow TA; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Wilson J; Early Oncology, R&D AstraZeneca, Cambridge CB10 1XL, UK.; Smith A; Early Oncology, R&D AstraZeneca, Cambridge CB10 1XL, UK.; Pilla Reddy V; Clinical Pharmacology and Quantitative Pharmacology, Biopharmaceuticals R&D, AstraZeneca, Cambridge SG8 6EE, UK.; Cadogan E; Early Oncology, R&D AstraZeneca, Cambridge CB10 1XL, UK.; Durant ST; Early Oncology, R&D AstraZeneca, Cambridge CB10 1XL, UK.; Reynolds CP; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. patrick.reynolds@ttuhsc.edu.; Department of Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Department of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Department of Internal Medicine, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.

Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE

Jucaite A; PET Science Centre, Precision Medicine and Biosamples, R&D, AstraZeneca, Stockholm, Sweden.; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.; Stenkrona P; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.; Cselényi Z; PET Science Centre, Precision Medicine and Biosamples, R&D, AstraZeneca, Stockholm, Sweden.; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.; De Vita S; Oncology R&D, AstraZeneca, Boston, Massachusetts, USA.; Buil-Bruna N; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.; Varnäs K; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.; Savage A; Oncology R&D, AstraZeneca, Cambridge, UK.; Varrone A; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.; Johnström P; PET Science Centre, Precision Medicine and Biosamples, R&D, AstraZeneca, Stockholm, Sweden.; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.; Schou M; PET Science Centre, Precision Medicine and Biosamples, R&D, AstraZeneca, Stockholm, Sweden.; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.; Davison C; Oncology R&D, AstraZeneca, Cambridge, UK.; Sykes A; Oncology R&D, AstraZeneca, Cambridge, UK.; Pilla Reddy V; Oncology R&D, AstraZeneca, Cambridge, UK.; Hoch M; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.; Vazquez-Romero A; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.; Moein MM; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.; Halldin C; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.; Merchant MS; Oncology R&D, AstraZeneca, Boston, Massachusetts, USA.; Pass M; Oncology R&D, AstraZeneca, Cambridge, UK.; Farde L; PET Science Centre, Precision Medicine and Biosamples, R&D, AstraZeneca, Stockholm, Sweden.; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.

Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE